FDA panel votes against Spectrum's lung cancer drug

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 23, 2022 at 12:12: AM
via Advisers to the U.S Food and Drug Administration on Thursday voted against recommending Spectrum Pharmaceuticals' (SPPI.O) experimental drug for the treatment of patients with a form of non-small cell lung cancer.

article source
 

<



Similar threads

cafead
FDA panel votes against MDMA therapy for PTSD, citing muddy data and safety concerns
Replies
0
Views
37
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA panel votes against diabetes implant due to safety concerns
Replies
0
Views
64
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA advisory panel votes unanimously that Pfizer and Moderna shots be authorized for young...
Replies
0
Views
107
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA panel questions Roche’s Tecentriq-Abraxane combo in breast cancer, but votes to keep...
Replies
0
Views
253
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA Panel Votes 8-7 in Favor of Mallinckrodt&#039;s HRS-1 Drug
Replies
0
Views
121
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote